US 12,275,737 B2
Polymorphs of a kinase inhibitor, pharmaceutical compositions containing such a compound, preparation methods, and applications
Xiaodong Wang, Chapel Hill, NC (US); Weihe Zhang, Vestavia, AL (US); Xiangyong Liu, Zhejiang (CN); Changlong Han, Zhejiang (CN); and Zongquan Li, Zhejiang (CN)
Assigned to Meryx, Inc., Chapel Hill, NC (US)
Appl. No. 17/594,104
Filed by Meryx, Inc., Chapel Hill, NC (US); The University of North Carolina at Chapel Hill, Chapel Hill, NC (US); and Betta Pharmaceuticals Co., Ltd, Zhejiang (CN)
PCT Filed Apr. 1, 2020, PCT No. PCT/US2020/026167
§ 371(c)(1), (2) Date Oct. 1, 2021,
PCT Pub. No. WO2020/205967, PCT Pub. Date Oct. 8, 2020.
Claims priority of provisional application 62/828,055, filed on Apr. 2, 2019.
Prior Publication US 2022/0162214 A1, May 26, 2022
Int. Cl. C07D 487/04 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01)
CPC C07D 487/04 (2013.01) [A61K 31/519 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07B 2200/13 (2013.01)] 16 Claims
 
1. A crystal form of the compound of Formula I, its hydrate and/or a solvate thereof,

OG Complex Work Unit Chemistry
wherein the crystal form is characterized by an X-ray powder diffraction pattern comprising peaks at 5.7±0.2°, 17.7±0.2°, 19.7±0.2°, 22.7±0.2°, and 23.2±0.2° degrees 2θ.